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Franz VolhardWolfgang Kiowski, M.D. (1949–2012) was a German physician-scientist who made exemplary contributions to
clinical research in human physiology, heart failure, arterial hypertension, and endothelin science. His academic
career took him from Heinz Losse, M.D. at the University of Münster, Germany, to the University of Michigan,
U.S.A., to work with Stevo Julius, M.D. In 1979, Kiowski was recruited to the University of Basel in Switzerland
and ultimately moved to the Hospital of the University of Zürich in Switzerland. Twenty years ago, Kiowski
published a landmark study pioneering the use of endothelin receptor antagonists (ERAs) in patients (Lancet
1995; 346: 732–736), which introduced a new therapeutic principle to human medicine. During his career, he
published numerous studies in the area of pathophysiology, clinical pharmacology (particularly calcium channel
blockers, ERAs, and PDE5 inhibitors), heart failure, cardiac transplantation, coronary artery disease, and many
case reports from his clinical work. Kiowski was an active mentor and trained many young physicians and
physician-scientists. He died unexpectedly in Zürich during the planning stages of the Thirteenth International
Conference on Endothelin to be held in Tokyo in 2013. This article summarizes Kiowski's achievements, his role
as a mentor and as the human being he was. He will be remembered as a role model of an outstanding, curious
clinician who was highly successful as a physician, scientist, and teacher, and at the same time managed to
enjoy many hobbies and life with his family. Referring to Wolfgang Kiowski, the article closes with a “It can be
done!”—message to young physician-scientists by Dr. Stevo Julius.
© 2014 Published by Elsevier Inc.G22, Winterthurerstrasse 190,
1 44 635 6875.Wolfgang Kiowskiwas born on April 27, 1949 in the city of Reckling-
hausen in postwar Germany, where he grew up. He graduated from
Carl-Friedrich-Gauss Gymnasium in 1968. In the same year, Wolfgang
matriculated at the University of Münster, Westfalen, where he obtain-
ed his M.D. in 1974 (Heagerty and Julius, 2013; Kjeldsen and Mancia,
2013). Wolfgang was awarded his doctorate (D.M. degree) “summa
cum laude” in 1975 at the Institute of Biochemistry for this medical the-
sis, forwhich he received the faculty's prize for the bestmedical thesis of
that year from the University of Münster. Meanwhile, Wolfgang had
joined the medical policlinic of the Department of Medicine of the
Münster University Hospital to work with Heinz Losse, M.D. (Fig. 1),
who had worked under Franz Volhard in Frankfurt (Luft and Dietz,
1993). Prof. Losse was one of Germany's most respected hypertension
researchers of the second half of the 20th century (Heintz and Losse,
1973; Losse, 1966; Rahn, 2006) (Fig. 2). Thus, Wolfgang continued a
pedigree of some of Germany's foremost clinicians and biomedical sci-
entists of the past 200 years, which goes back to Pﬂüger (Hierholzer
and Ullrich, 1999), Naunyn, and Schmiedeberg (Starke, 1998) (Fig. 2);
he was bound to become one himself.
In 1976, after his internship (“Medizinalassistent”) at theDepartment
of Medicine of the Münster University Hospital and the Chirurgische
Fig. 1. Heinz Losse, M.D. (left), German hypertension researcher and Physician-in-Chief of the medical policlinic at the Department of Medicine of the University of Münster Hospital in
Germany who became the ﬁrst mentor of Wolfgang Kiowski, M.D. (middle, ca. 2005). Prof. Losse paved the way to start an academic career in clinical research which ﬁrst took him to
the University of Michigan in 1976 to work with Stevo Julius, M.D. (right).
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Losse secured him a position as a postdoctoral fellow at the University
of Michigan in the United States to work with Stevo Julius, M.D., a re-
nowned expert in the ﬁeld of hypertension research (Fig. 1) (Heagerty
and Julius, 2013; Kjeldsen and Mancia, 2013). During his time in
Michigan,Wolfgangmade seminal contributions, producing important pa-
pers on human physiology and blood pressure regulation (Julius et al.,
1983; Kiowski and Julius, 1978; Kiowski et al., 1981), and contributing
to the understanding of actions of antiadrenergic drugs (Simon
et al., 1977, 1978). Wolfgang and his wife Monika spent three years
in the United States where Wolfgang worked hard but also enjoyed
life (Fig. 3).
In 1979, at the age of 30 and recruited by Fritz Bühler,M.D.,Wolfgang
returned to Europe to the University of Basel in Switzerland (Fig. 4), and
joined the Department of Cardiology at the University Hospital
where he worked as a clinical fellow under Felix Burkhart, M.D. At
the same time, Wolfgang continued his research and developed his
own scientiﬁc focus that would also become his clinical expertise,
particularly the ﬁelds of arterial hypertension and heart failure. In
1984, he was appointed attending physician and head of the Hyper-
tension Service of the University Hospital Basel, where he was also inFig. 2. Scientiﬁc pedigree of Wolfgang Kiowski, M.D., which includes some of the focharge of cardiac surgery and post-cardiac transplant patients. In
1985, Wolfgang passed the habilitation requirements at the Univer-
sity of Basel, qualifying him for faculty rank. His habilitation thesis
discussed the role of sympathetic regulation in humans (Kiowski,
1985), work which he had begun a decade earlier in Dr. Julius'
laboratory (Julius et al., 1983; Kiowski and Julius, 1978; Kiowski
et al., 1981). During this time Wolfgang was hugely productive as a
scientist. For his scientiﬁc achievements Wolfgang was awarded
the Annual Scientiﬁc Prize of the Swiss Heart Foundation in 1992. In
the following year he was recruited as senior physician to the
University of Zurich's hospital division of cardiology (Fig. 4) to
work under its division chief, Hans-Peter Kräyenbühl, M.D., where
Wolfgang was in charge of the transplant and heart failure services.
In 1994, he was appointed Professor of Medicine at the University
of Basel, a position that he held until his untimely death.
Following Robert Furchgott's report of endothelial regulation of
vasomotor tone (Furchgott and Zawadzki, 1980), Wolfgang became
interested in the clinical aspects of this discovery. In the late 1980s, he
developed a keen interest in the newly discovered vasoconstrictor pep-
tide endothelin and its receptors, particularly in their antagonists as po-
tential new therapeutics for the treatment of cardiovascular disease,remost German clinicians and biomedical scientists of the past two centuries.
Fig. 3. Photograph picturing Wolfgang and Monika Kiowski canoeing in Michigan in the 1970s. Photo courtesy of Stevo Julius, M.D., and used with his permission.
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on Endothelin in Tsukuba, Japan (reviewed in Barton and Yanagisawa,
2008).
Within only months after the endothelin ETA and ETB receptors
were cloned in 1990 and 1991, respectively (reviewed in Barton and
Yanagisawa, 2008), Roche researchers had synthesized a smallmolecule
compound (RO-47 0203, later to be designated bosentan/Tracleer™) as
an endothelin receptor antagonist (ERA) optimized from its less potent
precursor RO-46 2005 (Clozel et al., 1993a, 1993b). The ﬁrst batch of
RO-47 0203 was synthesized and available already at the end of 1991
(Martine Clozel, M.D., personal communication 2014). In 1992, when
Wolfgang was still at the University of Basel he was approached by
Drs. Martine and Jean-Paul Clozel asking him to conduct a clinical
proof-of-concept study in patients with heart failure, using the newly
discovered orally active ERA. In 1994, bosentan as well as its acute
effects in chronic experimental heart failure were published (Clozel
et al., 1994; Teerlink et al., 1994). Meanwhile, Wolfgang had obtained
results fromhis study in heart failure patients (obtained in collaboration
with Osmund Bertel, M.D. at the Triemli City Hospital in Zürich) which
he submitted in the Fall of 1994 as a conference abstract to be presented
at the American College of Cardiology meeting in New Orleans, LA, in
the Spring of 1995 (Kiowski et al., 1995a). The same year, the full article
was published in the Lancet as the ﬁrst ever study of clinical use of an
ERA in patients (Kiowski et al., 1995b).
To our knowledge, these remain the only patient studies that
were ever published using an orally active antagonist targeting G
protein-coupled receptors within little more than three years after
the cDNA and peptide sequences of these receptors had been identiﬁed,
representing one of the fastest example of translational medicine in
history (Barton and Yanagisawa, 2008). It is noteworthy that both
events — the ﬁrst ever study to use an orally active ERA in patients
was performed at the Hospital of the University of Zurich, and the for-
mer Roche ERA brought into clinical application by the biopharma-
ceutical company Actelion newly founded in 1997 — originated
from Switzerland, a country with a relatively small population but
rather high scientiﬁc productivity (King, 2004).
Wolfgang did not slow down after publishing a landmark study
20 years ago (Kiowski et al., 1995b) but continued to explore therole of endothelin and cardiovascular disease in humans (Kiowski,
1991; Kiowski et al., 1991, 1994a, 1994b). He participated in several
large-scale clinical trials investigating ERAs in heart failure (Packer
et al., 2005; Spieker et al., 2000; Sutsch et al., 1997, 1998). Wolfgang
published a total of 28 articles on endothelin, including review arti-
cles written with one of the authors about therapeutic principles of
endothelin antagonism (Barton and Kiowski, 2001). In addition, as
a general cardiologist with broad knowledge and interests, he pub-
lished important studies in the area of pathophysiology (Brunner-
La Rocca et al., 1999), clinical pharmacology (particularly ERAs and
PDE5 inhibitors (Schalcher et al., 2002)), heart failure (Burkart and
Kiowski, 1991), cardiac transplantation (Brunner-La Rocca et al.,
1998), coronary artery disease (Kaiser et al., 2010), and case reports
of patients from his clinical work (Scharf et al., 2001).
Aside frombeing a dedicated clinician-scientist,Wolfgangwas also a
clinical teacher who shared his knowledge and experience with his
younger colleagues. During his cardiology fellowship in the Division of
Cardiology of the Hospital of the University of Zürich, one of the authors
(M.B.) ﬁrst-hand enjoyedmemorable clinical teaching and education in
pathophysiology, as well as ﬁrst-rate examples of physician–patient
relationships that he remembers to this day. Occasionally, Wolfgang
trusted him to take care of his private patients when he was busy
doing coronary interventions in the cath lab or away at a conference.
The words that Wolfgang's patients had for him were always of the
highest praise and admiration.Wolfgang himselfwasmodest in his clin-
ical everyday work, and ﬁrstly and above all focused on his patients.
Wolfgang was a true physician role model.
Academic medicine would not be possible without mentorship
(Barton and Pollock, 2012), and Wolfgang was active as a mentor to
his fellows. Wolfgang's team was always important to him. Wolfgang
cared about the people who hewas workingwith, recalls one of his for-
mer fellows, Hans-Peter Brunner-La Rocca, (Brunner-La Rocca, 2014)
who now holds the Chair “Cardiology with a Focus on Clinical Heart
Failure” at the Faculty of Health, Medicine and Life Sciences at the
University of Maastricht where Dr. Brunner-La Rocca serves as Vice
Chair of the Department of Cardiology and head of the Department of
Clinical Heart Failure at Maastricht University Medical Center. Dr.
Brunner remembers that Wolfgang's interest in the individual was
Fig. 4. Graphic summary of Wolfgang Kiowski's academic career as summarized by Dr. Stevo Julius for a lecture given at the 2013 meeting of the European Society of Hypertension in his
memory. Figure courtesy of Stevo Julius, M.D., and used with his permission.
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1994. Hehad initially planned to become a cardiologist working in a pri-
vate practice and had basically no experience in research. He started
working inWolfgang's teamon theheart failure service and cardiac trans-
plant care. Twenty years later, Dr. Brunner is still enthusiastic about clin-
ical research andhismain clinical and research focus remains heart failure
which, he thinks, says a lot. He remembers thatWolfgangwas able to en-
thuse people says that in contrast tomany so-called leaders in theﬁeld, he
was genuinely interested in and cared for the individual.WhenWolfgang
realized Dr. Brunner's passion for computing and information technology,
hemade time available and allowedhim to set up a central databaseusing
already existing, but unstructured data.Wolfgang also taught Dr. Brunner
how to correctly analyze data from a scientiﬁc point of view. As a result,Fig. 5.A composition of photographs ofWolfgang andMonika Kiowski pictured in front of the T
fellowship at University of Michigan in the 1970s (right). Photograph courtesy of Stevo Julius,Dr. Brunner published his ﬁrst article as ﬁrst author in one of the
top journals in the ﬁeld (Brunner-La Rocca et al., 1996). Importantly,
Wolfgang not only gave Dr. Brunner the opportunity to pursue a research
fellowship at the University of Melbourne in Australia with one of his for-
mer colleagues from his Ann Arbor days, Murray Esler, M.D. (Brunner-La
Rocca et al., 2001, 2002), but also guaranteed him a senior staff position
upon his return to Switzerland, a promisewhich according to Dr. Brunner
Wolfgang kept even against the strong opposition from within the divi-
sion. Without Wolfgang, he would not be where and what he is today,
says Dr. Brunner.
Wolfgang had the ability to motivate younger colleagues to enter
cardiology and was even able to foresee the future development of
cardiology. In the late 1990s, the internal medicine resident ChristophajMahal in Agra, India, a few years before his untimely death (left) and during the research
M.D., and used with his permission.
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diology.Wolfgang responded: “If I were to be young again I would choose
electrophysiology and get into how to ablate atrial ﬁbrillation”. This was
long before ablation of atrial ﬁbrillation became a clinical treatment
option, and only initial ﬁrst results had been published at the time
(Haissaguerre et al., 1998). Wolfgang motivated his young colleague
to obtain licensure in the U.S. and tomove to theUniversity ofMichigan,
the same institution where he had trained 25 years earlier. After com-
pleting a clinical cardiology fellowship and research with Fred Morady,
M.D. (Oral et al., 2002; Scharf et al., 2009), Dr. Scharf returned to Zürich
to introduced the new technique in Switzerland and joined his mentor
at the Zürich Cardiovascular Center (HGZ Zürich).
Another of Wolfgang's successful mentees is Erwin Oechslin, M.D.,
now Professor of Cardiology at the University of Toronto in Canada,
where Dr. Oechslin heads the world's largest program of adult patients
with congenital heart disease andwhere he continued to do research to-
gether with Wolfgang (Oechslin et al., 2005).
At scientiﬁc meetings, Wolfgang was known to strongly present
his views and argue convincingly with his peers about issues that did
matter to him. For several decades Wolfgang was active in medical
societies, such as the European Society of Hypertension and the Swiss
Society of Cardiology, and he was elected Fellow of the European Society
of Cardiology and Fellow of the American College of Cardiology. For
many yearsWolfgangwas on the editorial board ofmedical journals, in-
cluding the European Heart Journal, and also served on the scientiﬁc ad-
visory boards of the International Conferences on Endothelin (including
ET-6 held in 1999 in Montréal, Canada).
The last decade of his lifeWolfgang spent at the HGZ Zürich after he
left the University Hospital (Fig. 4).Wolfgang until the time of his death
remained one of Switzerland's most respected experts in heart failure,
invasive and general cardiology.Wolfgang hadmany hobbies, including
windsurﬁng, and he can serve as a prime example of someone who is
successful as a physician, scientist, and father who enjoyed life with
his family and his wife Monika (Fig. 5). Wolfgang Kiowski — according
to Dr. Julius in a message to young colleagues given at the 2013 ESH
meeting — was a great example who demonstrated that this can be
done and that you do not need to be obsessed with work and that
you can enjoy life in academic medicine (Fig. 6).
Wementioned earlier the reminiscences of one author of this article
onWolfgang. For the other author (E.L.S.), whometWolfgangmainly atFig. 6. The ﬁnal slide of the lecture delivered by Stevo Julius, M.D. inmemory of Wolfgang
Kiowski at the 2013 European Society of Hypertension (ESH) meeting in Milan, Italy. The
slide summarizes personality, abilities and achievements of Wolfgang Kiowski and at
the same time represents a motivating message from Stevo Julius to all young colleagues
and embarking on a career in cardiovascular medicine and science. Figure courtesy of
Stevo Julius, M.D., and used with his permission.scientiﬁc meetings, and was invited to his home and enjoyed the com-
pany of him and his wife Monika, Wolfgang was a superb physician-
scientist with a deep understanding of cardiovascular physiology and
pathophysiology. His varied interests, his humor, and his empathy as
well as his rigorous intellect were compelling. It was a real pleasure to
exchange about any subject with him, scientiﬁc or other, and a pleasure
to see him with Monika, since they evidently enjoyed each other so
much (Fig. 5).
Wolfgangwas an avid photographer. He did not let go of this passion
until the last day of his life: in the morning cycling to work, Wolfgang
took a picture of the Zurich skyline overlooking Lake Zürich just after
sunrise (Fig. 7). After his last clinical assignment at the HGZ Zürich on
that day, he took his bike to cycle back home when he stopped to take
his last picture, now the mountain skyline facing Lake Zürich in the
last sunlight shortly before sunset (Fig. 7). Only minutes after taking
this picture he suffered a massive myocardial infarction which
was too extensive to allow recovery (Heagerty and Julius, 2013;
Kjeldsen and Mancia, 2013). On November 25, 2012, Wolfgang
Kiowski died of heart failure, a clinical syndrome that was the center
of his clinical and scientiﬁc interest for his entire professional life.
Wolfgang's ﬁrst academic teacher and mentor Prof. Losse has been
described by Karl-Heinz Rahn, M.D. (his successor at the University ofFig. 7. Two examples ofWolfgangKiowski's skills as a photographer, both taken on the last
day of his life before he succumbed to a fatal cardiac arrest due to myocardial infarction.
These photographs were shown by Stevo Julius, M.D. (who also provided the subtitles of
the slides), during a lecture given inmemory ofWolfgang Kiowski at the European Society
of Hypertension (ESH) meeting in 2013 Milan, Italy. Photographs courtesy of Stevo Julius,
M.D., and used with his permission.
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teacher able to create enthusiasm among his students” (Rahn, 2006).
The same is to be said about Prof. Losse's student Wolfgang Kioswki.
What hedid for his patients, for his trainees, for cardiovascularmedicine
and clinical endothelin research will not be forgotten. Wolfgang's
professional ethos is reﬂected in the words of Sir William Osler that
we quoted at the beginning of this article as well as in Osler's words
quoted below, an ethos that young physicians and trainees working
with Wolfgang Kiowski could experience in everyday clinical work.
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